These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 7577614)
21. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707 [TBL] [Abstract][Full Text] [Related]
22. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. Dhordain P; Albagli O; Honore N; Guidez F; Lantoine D; Schmid M; The HD; Zelent A; Koken MH Oncogene; 2000 Dec; 19(54):6240-50. PubMed ID: 11175338 [TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477 [TBL] [Abstract][Full Text] [Related]
24. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Loomis R; Carbone R; Reiss M; Lacy J Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752 [TBL] [Abstract][Full Text] [Related]
25. [Post-transplantation lymphomas and Epstein-Barr virus]. Caillard S; Heibel F; Benaicha M; Moulin B Nephrologie; 1998; 19(8):481-8. PubMed ID: 9894641 [TBL] [Abstract][Full Text] [Related]
26. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations. Greiner TC; Abou-Elella AA; Smir BN; Orazi A; Hinrichs S; Anderson J; Gross T; Bierman P; Hauke R Leuk Lymphoma; 2000 Aug; 38(5-6):563-76. PubMed ID: 10953978 [TBL] [Abstract][Full Text] [Related]
27. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124 [TBL] [Abstract][Full Text] [Related]
28. Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas. Bajalica-Lagercrantz S; Piehl F; Lagercrantz J; Lindahl J; Weber G; Kerckeart JP; Porwit-MacDonald A; Nordenskjöld M Leukemia; 1997 Apr; 11(4):594-8. PubMed ID: 9096701 [TBL] [Abstract][Full Text] [Related]
29. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Tanner JE; Alfieri C Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802 [TBL] [Abstract][Full Text] [Related]
30. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Capello D; Rossi D; Gaidano G Hematol Oncol; 2005 Jun; 23(2):61-7. PubMed ID: 16216037 [TBL] [Abstract][Full Text] [Related]
31. bcl-2 protein is strongly expressed in post-transplant lymphoproliferative disorders. Chetty R; Biddolph S; Kaklamanis L; Cary N; Stewart S; Giatromanolaki A; Gatter K J Pathol; 1996 Nov; 180(3):254-8. PubMed ID: 8958801 [TBL] [Abstract][Full Text] [Related]
33. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094 [TBL] [Abstract][Full Text] [Related]
34. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Delecluse HJ; Kremmer E; Rouault JP; Cour C; Bornkamm G; Berger F Am J Pathol; 1995 May; 146(5):1113-20. PubMed ID: 7747805 [TBL] [Abstract][Full Text] [Related]
35. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases. Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782 [TBL] [Abstract][Full Text] [Related]